1. Home
  2. SBS vs VTRS Comparison

SBS vs VTRS Comparison

Compare SBS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Companhia de saneamento Basico

SBS

Companhia de saneamento Basico

HOLD

Current Price

$30.19

Market Cap

18.4B

Sector

Utilities

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$15.09

Market Cap

14.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBS
VTRS
Founded
1954
1961
Country
Brazil
United States
Employees
N/A
30000
Industry
Water Supply
Medicinal Chemicals and Botanical Products
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4B
14.8B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
SBS
VTRS
Price
$30.19
$15.09
Analyst Decision
Hold
Analyst Count
0
6
Target Price
N/A
$11.83
AVG Volume (30 Days)
1.1M
9.3M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
2.93%
3.15%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,299,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.14
$1.60
P/E Ratio
$15.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.70
$6.85
52 Week High
$30.63
$16.47

Technical Indicators

Market Signals
Indicator
SBS
VTRS
Relative Strength Index (RSI) 69.48 54.14
Support Level $23.76 $9.63
Resistance Level N/A $16.30
Average True Range (ATR) 0.63 0.50
MACD 0.02 -0.14
Stochastic Oscillator 82.44 22.93

Price Performance

Historical Comparison
SBS
VTRS

About SBS Companhia de saneamento Basico

Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: